ONCOLOGY Vol 15 No 10 | Oncology

Advances in Cancer Research, Volume 79

October 01, 2001

In this time-honored series, the editors have assembled a panel of internationally recognized experts and accomplished a "tour de force" in presenting an overview of the past year’s most salient discoveries in cancer research. They have chosen

Physician Fee Cuts Also a Possibility

October 01, 2001

As if the prospective Medicare cuts in payments for outpatient chemotherapy drugs were not troubling enough, there is another dark Medicare cloud. The American Medical Association (AMA) is predicting that Medicare may also cut physician

Oncology Groups Protest Prospective Cut in Chemotherapy Reimbursement

October 01, 2001

Oncology groups are unhappy with the prospect that Medicare payments for chemotherapy drugs provided in outpatient settings could drop drastically in 2002. The Centers for Medicare and Medicaid Services (CMS) is considering a cut for

Testing Cancer Drugs in Children

October 01, 2001

A subcommittee of the Oncologic Drugs Advisory Committee (ODAC) recently spent a day discussing the similarities and differences between pediatric and adult hematologic malignancies. It was the second session in a series intended to advise the

Study Investigating Addition of Iressa to Conventional Treatment in Lung Cancer Patients

October 01, 2001

The Southwest Oncology Group (SWOG) is initiating a phase III trial (S0023) that will compare conventional chemoradiotherapy with consolidation docetaxel (Taxotere) followed by maintenance therapy with the investigational agent

Ibandronate vs Pamidronate in the Treatment of Malignant Hypercalcemia

October 01, 2001

Data from the first study to compare ibandronate with pamidronate (Aredia) in the treatment of malignant hypercalcemia were presented at the 37th annual meeting of the American Society of Clinical Oncology. The results demonstrated that rates

Addition of Trastuzumab to Chemotherapy Produces 50% Increase in Survival in Patients Selected by FISH

October 01, 2001

Results from three retrospective studies demonstrated that fluorescence in situ hybridization (FISH) testing of tumor tissue for HER2 gene amplification is an effective method of selecting women with HER2-positive metastatic breast cancer who will

FDA Approves Zoledronic Acid for the Treatment of Hypercalcemia of Malignancy

October 01, 2001

Novartis announced recently that it received marketing approval from the US Food and Drug Administration (FDA) for zoledronic acid (Zometa), a new generation intravenous bisphosphonate for the treatment of hypercalcemia of malignancy.

Thalidomide Plus Radiation Shows Promise in the Treatment of Certain Brain Tumors

October 01, 2001

According to a study conducted by the Radiation Therapy Oncology Group, thalidomide (Thalomid) in combination with radiation therapy shows promise in treating malignant brain tumors. Study findings were presented at the annual meeting of

Chemotherapy for Resectable and Advanced Pancreatic Cancer

October 01, 2001

This article will review the pertinent data on the use of chemotherapy for all stages of pancreatic cancer. For patients with metastatic disease, fluorouracil (5-FU) was the standard of care for several decades until a single

Prevalence of Complementary and Alternative Medicine Use in Cancer Patients

October 01, 2001

Interest in complementary and alternative medicine (CAM) has grown dramatically over the past several years. Cancer patients are always looking for new hope, and many have turned to nontraditional means. This study was

Chemotherapy for Resectable and Advanced Pancreatic Cancer

October 01, 2001

This article will review the pertinent data on the use of chemotherapy for all stages of pancreatic cancer. For patients with metastatic disease, fluorouracil (5-FU) was the standard of care for several decades until a single

Prevalence of Complementary and Alternative Medicine Use in Cancer Patients

October 01, 2001

Interest in complementary and alternative medicine (CAM) has grown dramatically over the past several years. Cancer patients are always looking for new hope, and many have turned to nontraditional means. This study was

Altered Fractionation for Head and Neck Cancer

October 01, 2001

A conventional course of radiation for squamous cell carcinoma in the United States is generally 70 Gy in 7 weeks, with a once-daily dose of 1.8 to 2 Gy. This schedule has a modest success rate in curing head and neck cancer. The

Prevalence of Complementary and Alternative Medicine Use in Cancer Patients

October 01, 2001

Interest in complementary and alternative medicine (CAM) has grown dramatically over the past several years. Cancer patients are always looking for new hope, and many have turned to nontraditional means. This study was

The Role of Amifostine as a Radioprotector

October 01, 2001

Effective radiotherapy for patients with cancer should include maximal tumor cell killing with minimal injury to normal tissue. Radiation doses that can be delivered, without causing severe damage to surrounding normal

Altered Fractionation for Head and Neck Cancer

October 01, 2001

A conventional course of radiation for squamous cell carcinoma in the United States is generally 70 Gy in 7 weeks, with a once-daily dose of 1.8 to 2 Gy. This schedule has a modest success rate in curing head and neck cancer. The

Chemotherapy for Resectable and Advanced Pancreatic Cancer

October 01, 2001

This article will review the pertinent data on the use of chemotherapy for all stages of pancreatic cancer. For patients with metastatic disease, fluorouracil (5-FU) was the standard of care for several decades until a single

Prevalence of Complementary and Alternative Medicine Use in Cancer Patients

October 01, 2001

Interest in complementary and alternative medicine (CAM) has grown dramatically over the past several years. Cancer patients are always looking for new hope, and many have turned to nontraditional means. This study was

Chemotherapy for Resectable and Advanced Pancreatic Cancer

October 01, 2001

This article will review the pertinent data on the use of chemotherapy for all stages of pancreatic cancer. For patients with metastatic disease, fluorouracil (5-FU) was the standard of care for several decades until a single

The Role of Amifostine as a Radioprotector

October 01, 2001

Effective radiotherapy for patients with cancer should include maximal tumor cell killing with minimal injury to normal tissue. Radiation doses that can be delivered, without causing severe damage to surrounding normal

Altered Fractionation for Head and Neck Cancer

October 01, 2001

A conventional course of radiation for squamous cell carcinoma in the United States is generally 70 Gy in 7 weeks, with a once-daily dose of 1.8 to 2 Gy. This schedule has a modest success rate in curing head and neck cancer. The

The Role of Amifostine as a Radioprotector

October 01, 2001

Effective radiotherapy for patients with cancer should include maximal tumor cell killing with minimal injury to normal tissue. Radiation doses that can be delivered, without causing severe damage to surrounding normal